This article has been retracted: please see Elsevier Policy on Article Withdrawal ( http://www.elsevier.com/locate/withdrawalpolicy ).

This article has been retracted at the request of the authors.

In this article, we claimed that Angptl-8, which we termed betatrophin and is also referred to in the literature as TD26, RIFL, C19orf80, and Lipasin, was the agent by which the insulin antagonist S961 induces robust β-cell replication in mice. Gusarova et al., in a Matters Arising article, subsequently showed that targeted Angptl-8/betatrophin overexpression in mice increases blood triglycerides but does not induce β-cell growth (Cell, 2014, 159, 691–696). When we repeated our original experiments with a larger number of mice, we also failed to observe β-cell expansion upon Angptl-8/betatrophin overexpression and reported these results in a Correspondence (Cell, 2014, 159, 467–468). We have subsequently repeated a series of blinded experiments with the Kushner lab and have now determined conclusively that our conclusion that Angptl-8/betatrophin causes specific β-cell replication is wrong and cannot be supported (PLoS One, 2016, 11, e0159276). Therefore, the most appropriate course of action is to retract the paper. We regret and apologize for this mistake.